Background {#Sec1}
==========

Known chromosomal alterations play a major role in perturbing male fertility \[[@CR1]\]. Reciprocal chromosomal translocations are the most common structural rearrangement, with an incidence in infertile males up to ten times higher than in fertile men \[[@CR2]\]. Balanced chromosomal translocations may cause the loss of genetic material at breakpoints and may result in failure of spermatogenesis \[[@CR3]\]. Individuals affected by such translocations exhibit reproductive problems such as infertility, recurrent pregnancy loss, and malformed offspring \[[@CR4], [@CR5]\]. These effects are related to the specific chromosomes and breakpoints involved in the translocation \[[@CR6], [@CR7]\]. Some breakpoints can disrupt the structure of an important gene, leading to spermatogenic or maturation disorders, and male infertility \[[@CR5]\]. Important genes associated with male infertility are located on chromosome 5. For example, *Camk4* (encoding Ca^2+^/calmodulin-dependent protein kinase IV) is located on chromosome 5q22.1, and is expressed in spermatids and associated with chromatin and nuclear matrix \[[@CR8]\]. Disrupted *CAMK4* expression may be associated with human male infertility \[[@CR8]\]. In addition, the *Spink13* gene (encoding serine protease inhibitor, Kazal-type 13), mapped on chromosome 5 at 5q32, was reported to be associated with sperm maturation \[[@CR9]\]. The breakpoint of 5p13 was shown to be related to impaired spermatogenesis \[[@CR10]\].

However, genetic counseling of male carriers of chromosomal translocations remains challenging. Preimplantation genetic diagnosis (PGD) is recommended for those exhibiting a balanced translocation. Microdissection testicular sperm extraction and in vitro fertilization accompanied by PGD increases the chance of these carriers fathering a healthy child \[[@CR11], [@CR12]\]. Clinical characteristics, including spontaneous abortion, do not differ between those couples who accept and those who decline PGD \[[@CR13]\]. A systematic review showed there was insufficient evidence that PGD improves the live birth rate in couples with repeated miscarriage and carrying a structural chromosome abnormality \[[@CR14]\]. In addition, the live birth rate in patients refused PGD and choosing to conceive naturally was reported to be 37--63% for the first pregnancy, and then a cumulative rate of 65--83% \[[@CR4]\]. Natural pregnancy success rates for couples in which the male carries a chromosomal translocation ranged from 30% to 70% \[[@CR15]\]. This suggests that continued attempts to conceive naturally are a viable option for successful pregnancy, however, the relationship between clinical features and chromosome structural abnormality warrants further study.

The present study was established to explore the clinical features and translocation breakpoints in carriers of balanced translocations involving chromosome 5. This paper also highlights the importance of genetic counseling for infertile men.

Methods {#Sec2}
=======

Patients {#Sec3}
--------

Between July 2010 and December 2016, 82 male carriers of chromosomal translocations who were experiencing infertility, or receiving counseling, were recruited from the outpatient's department at the Center for Reproductive Medicine, the First Hospital of Jilin University, Changchun, China. All patients underwent a thorough physical examination and semen analysis, and were required to complete a detailed questionnaire regarding their smoking habits, marital status, medical history, and working conditions. The study protocol was approved by the Ethics Committee of the First Hospital of Jilin University, and written informed consent was obtained from all participants.

Semen analysis {#Sec4}
--------------

Semen analysis was performed according to procedures recommended by the World Health Organization guidelines. If no sperm was found, sperm was analyzed by sedimenting semen samples through centrifugation. Patients with oligozoospermia were diagnosed as a sperm count less than 15 × 10^6^/ml in their last three semen samples (taken at intervals of 1--3 weeks). Azoospermia and oligozoospermia were defined as previously described \[[@CR5]\]. All analyses were performed at the same laboratory, and all data were accessed from medical records.

Cytogenetic analysis {#Sec5}
--------------------

Cytogenetic analysis was carried out on all patients. Peripheral blood (0.5 mL) was collected in sterile tubes containing 30 U/mL heparin. Lymphocytes were then cultured in appropriate culture medium (Yishengjun; Guangzhou Baidi Biotech, Guangzhou, China) for 72 h, and subsequently treated with 20 μg/mL colcemid for 1 h. G-banding of metaphase chromosomes and karyotype analysis were performed using previously described methods \[[@CR5]\]. Twenty metaphases were counted and 6 karyotypes were analyzed per patient. Karyotype nomenclature was described in accordance of ISCN2009. The resolution level of chromosome analysis was 400--550 band levels.

Analysis of the identified translocation breakpoints {#Sec6}
----------------------------------------------------

A search of translocations identified in chromosome 5 from infertile males was performed using PubMed. The keywords "chromosome / translocation / sperm" and "chromosome / translocation / abortion" were used for the PubMed search. The relationships of translocation breakpoints with male infertility and recurrent pregnancy loss were analyzed. Such searches were performed for a total of 106 carriers of chromosomal 5 translocations. This study included the cases of reciprocal chromosomal translocations involving chromosome 5 in reported papers, and excluded cases without breakpoints, females, newborns, and bone marrow detection involving chromosome 5.

Results {#Sec7}
=======

A total of 82 translocation carriers were detected in this study. Of these, nine (11%) were carriers of a chromosome 5 translocation, in which other chromosome abnormality had been excluded. Karyotype results and G-banding karyotypes from these nine patients are respectively summarized in Table [1](#Tab1){ref-type="table"} and Fig. [1](#Fig1){ref-type="fig"}. One case had azoospermia (pregestational infertility), while eight cases had normal semen. For the former, no AZF gene deletion was found. Of the later eight cases, it was evident that their partners were able to conceive, but had a tendency to miscarry (gestational infertility): three cases had experienced recurrent spontaneous abortions, two cases each experienced stillbirths, and three cases produced a phenotypically normal child confirmed by amniocentesis. For the other 73 cases of translocations, we will describe or have published in another study.Table 1Karyotypes of chromosome 5 translocation carriers and their clinical featuresInfertility causesClinical findingsKaryotypeGiemsa bandingPregestational infertilityAzoospermia46,XY,t(5;21)(q13;p12)Figure [1a](#Fig1){ref-type="fig"}Gestational infertilityNormal sperm density; a history of miscarriage, or normal fertility46,XY,t(4;5)(q31;p15)Figure [1b](#Fig1){ref-type="fig"}46,XY,t(5;11)(p14;p15)Figure [1c](#Fig1){ref-type="fig"}46,XY,t(5;13)(q13;q12)Figure [1d](#Fig1){ref-type="fig"}46,XY,t(5;18)(p13;p11)Figure [1e](#Fig1){ref-type="fig"}46,XY,t(5;18)(p15;q11.2)Figure [1f](#Fig1){ref-type="fig"}46,XY,t(5;20)(q13;q12)Figure [1g](#Fig1){ref-type="fig"}46,XY,t(5;21)(p13;q22)Figure [1h](#Fig1){ref-type="fig"}46,XY,t(5;22)(p11;p11)Figure [1i](#Fig1){ref-type="fig"}Fig. 1G-banding karyotype of the nine cases identified as possessing chromosome 5 translocations. **a**: t(5;21), **b**: t(4;5), **c**: t(5;11), **d**:t(5;13), **e**: t(5;18)(p13;p11), **f**: t(5;18)(p15;q11.2), **g**: t(5; 20), **h**: t(5;21), **i**: t(5;22)

A literature review was also performed, from which karyotype results, clinical manifestations, and breakpoints on chromosome 5 were collected, as shown in Table [2](#Tab2){ref-type="table"}. A total of 106 karyotypes included chromosome 5 translocations. The most common translocation was t(4;5), observed in 13 patients, followed t(5;8) (*N* = 11). Chromosomes 4(*N* = 13), 8(N = 11), 2,3,7,13(*N* = 7), 1,9,10,12(*N* = 6), 6, 18(*N* = 5), 15,20(*N* = 4),14,16,17(*N* = 3) and 11,19, X (N = 1) were respectively involved in the balanced translocation with chromosome 5.Table 2Breakpoints in chromosome 5 translocation carriers and clinical featuresCaseKaryotypeBreakpointsClinical findingsReference1t(1;5)1p32;5q31Severe oligoasthenoteratozoospermiaPeschka et al., 1999 \[[@CR27]\]2t(1;5)1p31.1;5q33.3NormozoospermiaBrugnon et al., 2006 \[[@CR28]\]3t(1;5)1p22;5q11Malformed/stillborn childrenMeza-Espinoza et al., 2008 \[[@CR29]\]4t(1;5)1q36.1;5q312 miscarriage, PGD and 2 term deliveryIkuma et al., 2015 \[[@CR4]\]5t(1;5)1q41;5q33Miscarriage and PGDKyu Lim et al., 2004 \[[@CR30]\]6t(1;5)1qter;5p14Recurrent miscarriageGoud et al., 2009 \[[@CR31]\]7t(2;5)2p25;5p12Teratozoospermia, Habitual abortionsVegetti et al., 2000 \[[@CR32]\]8t(2;5)2p21;5p15Recurrent spontaneous abortionGada Saxena et al., 2012 \[[@CR33]\]9t(2;5)2p13;5p15Recurrent fetal wastageFryns et al., 1998 \[[@CR34]\]10t(2;5)2p11;5q15AbortionTemplado et al., 1988 \[[@CR35]\]11t(2;5)2p11;5q31Recurrent abortionPortnoï et al., 1988 \[[@CR36]\]12t(2;5)2q12;5q35.3Recurrent pregnancy lossKochhar et al., 2013 \[[@CR22]\]13t(2;5)2q13.1;5q35.16 miscarriage, PGD and 1 term deliveryIkuma et al., 2015 \[[@CR4]\]14t(3;5)3p27;5p144 fetal lossesAdamoli et al., 1986 \[[@CR37]\]15t(3;5)3q13;5q35Repeated abortionsVenkateshwari et al., 2011 \[[@CR21]\]16t(3;5)3q26.2;5p15.1MiscarriageSugiura-Ogasawara et al., 2008 \[[@CR38]\]17t(3;5)3q27;5p15Normospermic, A boy 46,XY,t(3;5)patVozdova et al., 2013 \[[@CR11]\]18t(3;5)3q28;5p13Recurrent spontaneous abortionGada Saxena et al., 2012 \[[@CR33]\]19t(3;5)3q29;5q13Multiple abortionsCastle et al., 1988 \[[@CR39]\]20t(3;5)3q29;5q33.2PGDFindikli et al., 2003 \[[@CR40]\]21t(4;5)4p15.2;5p12NormozoospermiaWiland et al., 2007 \[[@CR41]\]22t(4;5)4p15;5q12OligozoospermiaPerrin et al., 2010 \[[@CR42]\]23t(4;5)4p14;5q13.1recurrent miscarriagePundir et al., 2016 \[[@CR43]\]24t(4;5)4q21;5p15Habitual miscarriageLi et al., 2012 \[[@CR23]\]25t(4;5)4q21;5p15Recurrent spontaneous abortionZhang M et al., 2015 \[[@CR44]\]26t(4;5)4q21;5q11.2Severe oligoasthenoteratozoospermiaPeschka et al., 1999 \[[@CR27]\]27t(4;5)4q22;5q352 fetal lossesAdamoli et al., 1986 \[[@CR37]\]28t(4;5)4q25;5p15.24 abortionsGhazaey et al., 2015 \[[@CR45]\]29t(4;5)4q31;5p15Recurrent spontaneous abortionsZhang et al., 2011 \[[@CR46]\]30t(4;5)4q31;5q13normozoospermiaHuang et al., 2007 \[[@CR47]\]31t(4;5)4q32;5q14OligoasthenoteratozoospermiaDohle et al., 2002 \[[@CR48]\]32t(4;5)4q32;5q14MiscarriageDul et al., 2012 \[[@CR49]\]33t(4;5)4q35;5p15Recurrent miscarriagesDutta et al., 2011 \[[@CR50]\]34t(5;6)5p15.3;6q13recurrent abortionKiss et al., 2009 \[[@CR51]\]35t(5;6)5p13.3;6q27Recurrent spontaneous abortionGada Saxena et al., 2012 \[[@CR33]\]36t(5;6)5q21;6q33Recurrent fetal wastageFryns et al., 1998 \[[@CR34]\]37t(5;6)5q33.1;6p11.2MiscarriageSugiura-Ogasawara et al., 2008 \[[@CR38]\]38t(5;6)5q35;6p21.3PGDKo et al., 2010 \[[@CR52]\]39t(5;7)5p15.2;7p14Recurrent spontaneous abortionGada Saxena et al., 2012 \[[@CR33]\]40t(5;7)5p13;7p15Recurrent pregnancy lossKochhar et al., 2013 \[[@CR22]\]41t(5;7)5p13;7p15Spontaneous abortionStephenson et al., 2006 \[[@CR53]\]42t(5;7)5p11;7q118 abortionsAl-Hussain et al., 2000 \[[@CR54]\]43t(5;7)5q13;7p15.12 miscarriagesEstop et al., 1995 \[[@CR55]\]44t(5;7)5q21;7q32NormozoospermiaCifuentes et al., 1999 \[[@CR56]\]45t(5;7)5q33;7q22Miscarriage and PGDKyu Lim et al., 2004 \[[@CR30]\]46t(5;8)5p14;8q22AsthenozoospermiaGodo et al., 2013 \[[@CR7]\]47t(5;8)5q22;8q24.1OligoasthenoteratozoospermiaMeschede et al., 1998 \[[@CR57]\]48t(5;8)5q22.1;8q23.2PGDKo et al., 2010 \[[@CR52]\]49t(5;8)5q23.1;8p23.24 miscarriage,1 term deliveryIkuma et al., 2015 \[[@CR4]\]50t(5;8)5q33.3;8q11.21Recurrent miscarriagePundir et al., 2016 \[[@CR43]\]51t(5;8)5q33;8q13NormozoospermiaBlanco et al., 1998 \[[@CR58]\]52t(5;8)5q33;8q13NormozoospermiaEstop et al., 2000 \[[@CR59]\]53t(5;8)5q33;8q13NormozoospermiaGodo et al., 2013 \[[@CR7]\]54t(5;8)5q33;8q13NormozoospermiaAnton et al., 2008 \[[@CR60]\]55t(5;8)5q35.1;8p11.2AstenozoospermiaAnton et al., 2008 \[[@CR60]\]56t(5;8)5q35.3;8q22.1Recurrent fetal wastageFryns et al., 1998 \[[@CR34]\]57t(5;9)5p15.1;9q22.1Normospermic, Primary infertilityVozdova et al., 2013 \[[@CR11]\]58t(5;9)5p13;9q22PGDZhang et al., 2014 \[[@CR61]\]59t(5;9)5q10;9q10Recurrent spontaneous abortionsRouen et al., 2017 \[[@CR62]\]60t(5;9)5q21;9q342 fetal lossesAdamoli et al., 1986 \[[@CR37]\]61t(5;9)5q23.2;9q22.3Spontaneous abortionStephenson et al., 2006 \[[@CR53]\]65t(5;9)5q23.3;9p24Recurrent miscarriageIyer et al., 2007 \[[@CR63]\]63t(5;10)5p13.3;10p12.2PGDKo et al., 2010 \[[@CR52]\]64t(5;10)5q22;10q11.2PGDKo et al., 2010 \[[@CR52]\]65t(5;10)5q22;10q22MiscarriageSugiura-Ogasawara et al., 2008 \[[@CR38]\]66t(5;10)5q34;10p12.1Recurrent spontaneous abortionsRouen et al., 2017 \[[@CR62]\]67t(5;10)5q35;10q22Spontaneous abortionsBourrouillou et al., 1986 \[[@CR64]\]68t(5;10)5q35;10q24Recurrent miscarriageGoud et al., 2009 \[[@CR31]\]69t(5;11)5p14;11p15Normozoospermia[Zhang HG](https://www.ncbi.nlm.nih.gov/pubmed/?term=Zhang%20HG%5BAuthor%5D&cauthor=true&cauthor_uid=26782529) et al., 2015 \[[@CR5]\]70t(5;12)5p15.1;12p12.2Spontaneous abortionStephenson et al., 2006 \[[@CR53]\]71t(5;12)5p15.1;12q21InfertilityRavel et al., 2006 \[[@CR65]\]72t(5;12)5p14;12q15Recurrent spontaneous abortionGada Saxena et al., 2012 \[[@CR33]\]73t(5;12)5q11;12p1310 abortionsAl-Hussain et al., 2000 \[[@CR54]\]74t(5;12)5q13;12q13Recurrent spontaneous abortionsRouen et al., 2017 \[[@CR62]\]75t(5;12)5q35.1;12q24.1Repeated miscarriageGoddijn et al., 2004 \[[@CR66]\]76t(5;13)5p13;13q34Neonatal deathZhang et al., 2006 \[[@CR67]\]77t(5;13)5q11;13q333 spontaneous abortionsPellestor et al., 1989 \[[@CR68]\]78t(5;13)5q13;13q12Normozoospermia[Zhang HG](https://www.ncbi.nlm.nih.gov/pubmed/?term=Zhang%20HG%5BAuthor%5D&cauthor=true&cauthor_uid=26782529) et al., 2015 \[[@CR5]\]79t(5;13)5q15;13p12OligozoospermiaMatsuda et al., 1992 \[[@CR69]\]80t(5;13)5q21;13q12.12 miscarriage, no conceptionIkuma et al., 2015 \[[@CR4]\]81t(5;13)5q33;13q12InfertilityMikelsaar et al., 2012 \[[@CR20]\]82t(5;13)5q34;13q33Recurrent miscarriageIyer et al., 2007 \[[@CR63]\]83t(5;14)5p13;14q11.2PGDZhang et al., 2014 \[[@CR61]\]84t(5;14)5p13;14q23Spontaneous abortionsBourrouillou et al., 1986 \[[@CR64]\]85t(5;14)5q11.2;14q32.1Spontaneous abortionStephenson et al., 2006 \[[@CR53]\]86t(5;15)5p15.2;15q21.1PGDKo et al., 2010 \[[@CR52]\]87t(5;15)5p13.3;15q15.3PGDKo et al., 2010 \[[@CR52]\]88t(5;15)5q35;15q22Pregnancy of PGDEscudero et al., 2003 \[[@CR70]\]89t(5;15)5q35;15q26.2Abnormal semen, 2 IVF-ETVozdova et al., 2013 \[[@CR11]\]90t(5;16)5q13; 16p13.1NormozoospermiaHaapaniemi Kouru et al., 2017 \[[@CR71]\]91t(5;16)5q33;16p13Recurrent pregnancy lossKochhar et al., 2013 \[[@CR22]\]92t(5;16)5q33.3;16p13.3Recurrent miscarriagesDutta et al., 2011 \[[@CR50]\]93t(5;17)5q13.2;17q21.2infertilityMau et al., 1997 \[[@CR72]\]94t(5;17)5q31;17p13NormozoospermiaAnton et al., 2008 \[[@CR60]\]95t(5;17)5q33.1;17q25.3Repeated miscarriageGoddijn et al., 2004 \[[@CR66]\]96t(5;18)5p15;18q11.2Spontaneous abortion[Zhang HG](https://www.ncbi.nlm.nih.gov/pubmed/?term=Zhang%20HG%5BAuthor%5D&cauthor=true&cauthor_uid=26782529) et al., 2015 \[[@CR5]\]97t(5;18)5p15;18q21Malformed childrenBalkan et al., 1983 \[[@CR73]\]98t(5;18)5q15;18q22Spontaneous abortionsSoh et al., 1984 \[[@CR74]\]99t(5;18)5q15;18q232 fetal lossSmith et al., 1990 \[[@CR75]\]100t(5;18)5q31.1;18q21.1PGDKo et al., 2010 \[[@CR52]\]101t(5;19)5q15;19p12Normospermic, A boy 46,XY,t(5;19)patVozdova et al., 2013 \[[@CR11]\]102t(5;20)5q22;20p13Asthenozoospermia, Habitual abortionsVegetti et al., 2000 \[[@CR32]\]103t(5;20)5q13;20q12Normozoospermia[Zhang HG](https://www.ncbi.nlm.nih.gov/pubmed/?term=Zhang%20HG%5BAuthor%5D&cauthor=true&cauthor_uid=26782529) et al., 2015 \[[@CR5]\]104t(5;20)5q22;20p12Recurrent fetal wastageFryns et al., 1998 \[[@CR34]\]105t(5;20)5q31;20p13AzoospermiaPoli et al., 2016 \[[@CR18]\]106t(X;5)Xp22.1;5p11AzoospermiaPeschka et al., 1999 \[[@CR27]\]

The most common breakpoint, at 5p15, was observed in 11 patients, followed by 5q13 (*N* = 10). Breakpoints at 5p14, 5p11, 5q13, 5q14, 5q15, 5q22, 5q31, 5q35 and 5q35.1 were found with cases of both pregestational and gestational infertility. All breakpoints were associated with gestational infertility (Table [3](#Tab3){ref-type="table"}).Table 3Incidence of breakpoints on chromosome 5BreakpointsNumber of patients with pregestational infertilityNumber of patients with gestational infertilityp15.31p15.23p15.14p1511p1415p13.33p139p122p1112q101q113q11.22q121q1319q13.11q13.21q1411q1514q214q2223q22.11q23.11q23.21q23.31q3123q31.11q338q33.12q33.21q33.33q342q3516q35.112q35.32

Discussion {#Sec8}
==========

In clinical practice, male infertility can be broadly divided into two types of reproductive failure: pregestational and gestational infertility \[[@CR16]\]. In the present study, nine of our cases were identified as carriers of chromosome 5 translocations, and we also reviewed 106 cases of chromosome 5 translocation reported in the literature. The breakpoints that we identified on chromosome 5 were found to be associated with pregestational or gestational infertility. One case was associated with pregestational infertility and eight cases were related to gestational infertility. Mikelsaar et al. \[[@CR17]\] and Venkateshwari et al. \[[@CR18]\] reported that the breakpoints at 5q33 and 5q35 in male carriers were associated with infertility. Kim et al. \[[@CR19]\] reported that the breakpoint at 5p13 could interfere with spermatogenesis, and that breakpoints at 5q15, 5q21.2, 5q22 and 5q32 were related to recurrent abortion. To study the relationship of these breakpoints on chromosome 5 with male infertility, we analyzed recent published literature and revealed clinical features in carriers of chromosome 5 translocations. The karyotype results and clinical findings at chromosome 5 are summarized in Table [2](#Tab2){ref-type="table"}. A common clinical feature associated with the breakpoints at 5p13, 5q33 and 5q35 was recurrent miscarriage, which was not consistent with the above reports.

Male infertility affects about 50% of couples unable to achieve pregnancy \[[@CR20]\]. Chromosomal abnormalities are closely related to male infertility \[[@CR21]\], and cytogenetic detection can provide valuable information for genetic counseling of infertile males \[[@CR22]\]. Previous reports have shown that infertile men have an 8--10-fold higher prevalence of chromosomal abnormalities than fertile men \[[@CR19]\]. Chromosomal translocation alters the complex and vital process of spermatogenesis, and leads to male infertility \[[@CR20]\]. Chromosome 5 translocation has often been associated with male infertility or recurrent pregnancy loss \[[@CR17], [@CR18], [@CR23]\].

Table [3](#Tab3){ref-type="table"} shows that all breakpoints were associated with gestational infertility. These cases indicated that such breakpoints were not responsible for pregestational infertility, so another breakpoint of translocation must be responsible in these individuals. For instance, two individuals with the breakpoint 5q22 were associated with pregestational infertility, and exhibited clinical features of oligoasthenoteratozoospermia and asthenozoospermia (case 47 and 102, respectively, Table [2](#Tab2){ref-type="table"}). The corresponding breakpoints of translocation in case 47 and 102 were 8q24.1 and 20p13, respectively. Kott et al. \[[@CR24]\] reported that the primary ciliary dyskinesia-19 (*CILD19*) gene (OMIM: 614,935), mapped to chromosome 8q24, was associated with asthenospermia in infertile males. Previous studies have shown that the sperm flagellar protein 1 (*SPEF1*) gene (OMIM: 610,674) located on chromosome 20p13 was be associated with curvature of microtubule bundles and the axoneme of sperm flagella \[[@CR25]\]. Previous studies suggested that disruptions of *CAMK4* located on chromosome 5q22.1, *SPINK13* located on chromosome5q32 and the testis-specific serine/threonine kinase ([*TSSK1B*](http://www.genenames.org/cgi-bin/gene_symbol_report?match=TSSK1B)) gene mapped to chromosome 5q22.2 were associated with loss of sperm function and human male infertility \[[@CR8], [@CR9], [@CR26]\]. In addition, the most common breakpoint, mapped to 5p15, was associated with gestational infertility. Other breakpoints were also identified as being associated with gestational infertility. For those affected by these breakpoints, natural conception remained possible with the potential to have normal children. For example, Ikuma et al. \[[@CR4]\] reported that the live birth rate with natural conception for translocation carriers was 65%--83% cumulatively. However, natural conception has a greater risk. The number of chromosomal unbalanced gametes is large, leading to repetitive pregnancy loss, and may have repercussions on the fertility of translocation carriers. For these carriers, informed choice should be provided during genetic counseling.

The major limitation of our present study was the relatively small number of carriers of chromosome 5 translocations. Furthermore, we did not investigate the specific molecular effects of the translocations by molecular-cytogenetic methods.

Conclusions {#Sec9}
===========

In the present study, 115 carriers of chromosome 5 translocations were reviewed. The most common translocation and breakpoint were t(4;5) and 5p15, respectively. All breakpoints at chromosome 5 were associated with gestational infertility. In genetic counseling, physicians should consider chromosome 5 and its breakpoints. Carriers of chromosome 5 translocations maybe choose to continue with natural conception or use available assisted reproductive technologies, such as preimplantation genetic diagnosis.
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